These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21672693)

  • 1. Monoclonal antibody therapy and progressive multifocal leukoencephalopathy.
    Jackson AC
    Can J Neurol Sci; 2011 Jul; 38(4):545-6. PubMed ID: 21672693
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Keene DL; Legare C; Taylor E; Gallivan J; Cawthorn GM; Vu D
    Can J Neurol Sci; 2011 Jul; 38(4):565-71. PubMed ID: 21672696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.
    Calabrese LH; Molloy ES; Huang D; Ransohoff RM
    Arthritis Rheum; 2007 Jul; 56(7):2116-28. PubMed ID: 17599729
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
    J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications.
    Greenlee JE
    Int MS J; 2006 Nov; 13(3):100-7. PubMed ID: 17101078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.
    Mc Govern EM; Hennessy MJ
    J Neurol; 2013 Feb; 260(2):665-7. PubMed ID: 23212753
    [No Abstract]   [Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn.
    Koutsavlis I
    Ann Hematol; 2021 Jan; 100(1):1-10. PubMed ID: 33009935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare neurological condition linked to newer monoclonal antibody biologics.
    Kuehn BM
    JAMA; 2009 Apr; 301(14):1423-4. PubMed ID: 19351930
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeted therapy and progressive multifocal leukoencephalopathy].
    Takao M
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():869-76. PubMed ID: 26480807
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy.
    Hohlfeld R
    Lancet Neurol; 2019 Jul; 18(7):623-624. PubMed ID: 31104991
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating.
    Carson KR; Bennett CL
    Leuk Lymphoma; 2009 Mar; 50(3):323-4. PubMed ID: 19347724
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML: underdiagnosed in MS patients on natalizumab.
    Steiner I
    Lancet Neurol; 2010 Jun; 9(6):564; author reply 564-5. PubMed ID: 20494319
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM
    N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.
    Küpper C; Heinrich J; Kamm K; Bücklein V; Rothenfusser S; Straube A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):e628. PubMed ID: 31597693
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy.
    Mahler C; Andrews M; Henson SM; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32434801
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
    Beudel M; Rövekamp F; van de Beek D; Brouwer M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34039733
    [No Abstract]   [Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab.
    Tuccori M; Focosi D; Maggi F; Cosottini M; Meini B; Lena F; Blandizzi C; Del Tacca M; Petrini M
    Ann Hematol; 2010 May; 89(5):519-22. PubMed ID: 19727726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.